Duke logo

Incyte INCB 39110-209 Ph2 Itacitinib PMF, PET-MF and PV-MF - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn about the effects of the drug itacitinib taken with ruxolitinib or itacitinib alone.

What is the Condition Being Studied?

Myelofibrosis

Who Can Participate in the Study?

Adults who:
- Have a confirmed diagnosis of PMF, PPV-MF, or PET-MF
- Have a bone marrow biopsy specimen available or willingness to undergo a bone marrow biopsy
- Have a life expectancy of at least 24 weeks
- Have an ECOG performance status of 0, 1, or 2.

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
- Get blood tests, MRIs, plasma lab tests as well as spleen/liver assessments
- Have Lipid panel test (measuring how much fat you have in your blood)
- Have multiple discussions about your current and past health

Study Details

Full Title
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Principal Investigator
Hematologist
Protocol Number
IRB:PRO00086011
NCT:NCT03144687
Phase
Phase II
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
studyrecruitment@duke.edu
or
919-681-5698